BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Drug Discovery

Zai Lab’s KarXT NDA Accepted by China’s NMPA for Schizophrenia Treatment

Zai Lab Limited announced that China’s National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for KarXT for the ...

January 20, 2025 | News

AstraZeneca and Daiichi Sankyo’s DATROWAY Secures First US Approval for HR-Positive, HER2-Negative Breast Cancer

First approval in the US for AstraZeneca and Daiichi Sankyo’s DATROWAY based on TROPION-Breast01 results showing 37% reduction in the risk of d...

January 20, 2025 | News

Innovent and ASK Pharm Secure NMPA Approval for Limertinib to Treat EGFR T790M-Mutated NSCLC

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

January 17, 2025 | News

Innovent Biologics Secures Breakthrough Therapy Designation for IBI343 in Advanced Pancreatic Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

January 16, 2025 | News

Iconovo and Lonza Join Forces to Develop Intranasal Biologic for Obesity Treatment

Lonza to develop spray-dried formulations for an intranasally-delivered biologic for Iconovo at its Center of Excellence for bioavailability enhancemen...

January 15, 2025 | News

China Approves Sarclisa-Pd for Relapsed Multiple Myeloma, Backed by Pivotal Trial and Real-World Data.

Approval based on positive pivotal ICARIA-MM phase 3 study using the China-based IsaFiRsT real-world study as bridging data, which demonstrated Sarclisa ...

January 13, 2025 | News

SN BioScience Secures FDA IND Clearance for SNB-101 Phase 1b/2 Trial, Targeting Extensive Stage Small Cell Lung Cancer

SN BioScience announced that its lead asset SNB-101 has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administra...

January 13, 2025 | News

Sciwind Biosciences Partners with Verdiva Bio in $2.4 Billion Deal to Advance Global Metabolic Disease Therapies

Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative therapies to treat metabolic diseases, ...

January 13, 2025 | News

Menarini Group Partners with Insilico Medicine on AI-Discovered Oncology Asset in $550M Licensing Deal

This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform, si...

January 13, 2025 | News

MSD’s GARDASIL® Becomes First HPV Vaccine Approved for Males in China

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the National Medical Products Administration (NMPA) of China ...

January 10, 2025 | News

UK Biobank Proteomics Project Partners with Thermo Fisher to Map Disease-Linked Proteins for Precision Medicine

UK Biobank Pharma Proteomics Project aims to create a comprehensive map of disease-associated protein levels in the human body to advance biomarker discove...

January 10, 2025 | News

Dizal’s China-Origin Sunvozertinib Secures FDA Priority Review for EGFR Exon20ins NSCLC

If approved, Sunvozertinib as a single oral drug would offer a convenient and safe treatment option with superior efficacy for NSCLC patients with E...

January 08, 2025 | News

Astellas Pharma Announces NMPA Approval of Zolbetuximab in China for Advanced Gastric and GEJ Cancer

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the National Medical Products Administration (N...

January 06, 2025 | News

Everest Medicines Announces NEFECON® NRDL Implementation in China to Expand Access for IgAN Patients

Everest Medicines (HKEX 1952.HK, 'Everest', or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing an...

January 06, 2025 | News

Stay Connected